Midazolam

• SYMBOL CLINICAL : Treatment of severe ocular chemical burns by subconjunctival injection of allogeneic mesenchymal stem cells: a multicentre… Pending
  2023-509713-37-00 Phase II 1 country Hopital Fondation Adolphe De Rothschild
• Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care: the PEDIADEX randomized controlled tria… Pending
  2025-521039-35-00 Phase III 1 country Centre Hospitalier Regional Universitaire De Tours
• Evaluation of a New Pain Management Regime for Oocyte Pick-Up During Fertility Treatment Pending
  2025-523018-10-00 Phase III/IV 1 country UZ Brussel
• A study for adolescents who are depressed and thinking of suicide Recruiting
  2024-518615-19-00 Phase III 4 countries Janssen Cilag International
• A study to test the safety and efficacy of a new drug, AZD3470, in patients with advanced solid tumours. Recruiting
  2023-506757-38-00 Phase I 3 countries Astrazeneca AB
• Impact of Analgesia on Success of External Version: Comparison of Spinal Anesthesia Versus Sedation; Prospective, Controlled, Randomized Stu… Recruiting
  2024-517302-29-00 Phase III 1 country Centre Hospitalier Universitaire Amiens Picardie
• Efficacy of dexmedetomidine versus midazolam sedation on extubation time in mechanically ventilated preterm infants: a randomized controlled… Recruiting
  2023-508785-16-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Advancing the quality of treatment and care for acute agitation in emergency psychiatry Recruiting
  2023-510201-18-00 Phase II/III 1 country Region Hovedstaden
• Remimazolam versus Midazolam for sedation during upper GI endoscopy: a randomized controlled trial Recruiting
  2024-516432-94-00 Phase IV 1 country Sint Antonius Ziekenhuis Stichting
• Regression of Atherosclerosis induced by liFe chAnging Experience with psiLocybin Recruiting
  2024-517902-27-00 Phase II 1 country Psyon s.r.o.
• FAST TRIAL Recruiting
  2024-515507-18-00 Phase III 1 country Odense University Hospital
• An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced… Recruiting
  2023-503865-48-00 Phase II 4 countries Taiho Oncology Inc.
• First-in-human, Phase 1/2, open-label, multicenter, dose-escalation and expansion study Recruiting
  2022-502645-99-00 Phase I (FiH) 2 countries Tango Therapeutics Inc.
• « Effect of sedative and anxiolytic sedation on children experience after general anesthesia » PEDIA_prem study. Recruiting
  2022-501124-23-00 Phase III 1 country Centre Hospitalier Universitaire De Montpellier
• Psilocybin - a strategy of rapid antidepressant response in depression comorbid with cancer,a randomized double-blind study with the possib… Recruiting
  2024-517747-31-00 Phase II 1 country Narodni Ustav Dusevniho Zdravi
• The effect of handheld-multimedia versus midazolam premedication on the level of perioperative anxiety in pediatric day-care. A randomized c… Recruiting
  2024-514642-37-00 Phase IV 1 country UZ Brussel
• Efficacy and Safety of Oral Midazolam for Providing Care to Patients Who Refuse Treatment and Have Moderately Severe to Severe Neurocognitiv… Ended
  2023-510277-33-00 Phase II 1 country Centre Hospitalier Universitaire Grenoble Alpes
• Antidepressant effects of psilocybin in pharmaco-resistant depression Ended
  2024-515899-13-00 Phase II 1 country Narodni Ustav Dusevniho Zdravi
• An Efficacy and Safety Study of JNJ-42756493 in Participants with Urothelial Cancer Ended
  2023-510273-34-00 Phase II 2 countries Janssen Cilag International
• Comparative Bioavailability of Midazolam 7.5 mg/1.5 mL Oromucosal Solution (Buccolam®) Versus 10 mg/2 mL Solution for Injection (Hypnovel®) … Ended
  2023-504903-10-00 1 country Laboratorios Lesvi S.L.
• Randomized Clinical Trial of Inhaled Sedation with Sevoflurane in Critically Ill Patients at Risk of Developing the Acute Respiratory Distre… Ended
  2024-517670-15-00 Phase III 1 country CHU Gabriel-Montpied
• Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants Ended
  2023-504461-23-00 Phase I (Other) 1 country Agomab Spain S.L.

Showing 1–22 of 22 trials